A further study indicates that both rapamycin and nebivolol may suppresses the up-regulation of miR-208a via inhibiting mTORC1 activation, thus increasing the level of MED13 and conferring the resistance of obesity (60). This evidence concerns the gene MED13 and obesity disorder.